News

Fresenius Kabi will exclusively commercialize Polpharma Biologics’ vedolizumab biosimilar candidate PB016 globally (except in the Middle East and North Africa).

Fresenius announced that the European Commission has granted approval for their denosumab biosimilars Conexxence®* and Bomyntra®* in Europe.

Dr. Wan Daud from Malaysia receives €100,000 research support through the JUMPstart Renal Nutrition Therapy Program to conduct her CKD nutrition study.

Recognized for service and innovation, Fresenius Kabi earns its 5th Premier award. Discover how we help hospitals improve care and reduce costs.

NutriKabina by Fresenius Kabi is a telehealth innovation that enables fast, accessible nutrition screening for oncology patients in hospitals across Argentina.

Fresenius Kabi advances responsible antibiotic manufacturing with AMR certification at its Portugal site: protecting public health for future generations.

mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, is pleased to announce that the European Commission has granted approval for its denosumab biosimilars Denbrayce® and Izamby®.

Fresenius Kabi’s fifth and sixth biosimilars Conexxence® (denosumab-bnht) and Bomyntra® (denosumab-bnht) are now available in the U.S. for all approved indications for their respective reference products, Prolia® (denosumab) and Xgeva® (denosumab).

Discover how Fresenius Kabi is expanding global R&D centers for Nutrition. Explore the new locations driving excellence.

Fresenius announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for the marketing authorization of its biosimilar candidates to Prolia® (denosumab) and Xgeva® (denosumab).

Discover best practices in perioperative nutrition from leading surgical experts. Four podcast episodes on surgery and nutrition management.

Q1/2025: Strong top line and excellent EPS growth, outlook confirmed

Lizl Veldsman from South Africa wins the award for her study on preventing muscle loss in ICU patients, supported by Fresenius Kabi's research grant.

Fresenius Kabi optimizes production network: Fresenius Kabi and EMS have signed an agreement to transfer the ownership of Fresenius Kabi's production site in Anápolis, Brazil, to EMS.

Fresenius announced that the Biologics License Application (BLA) for the denosumab biosimilars Conexxence®** (denosumab-bnht) and Bomyntra®** (denosumab-bnht) of its operating company Fresenius Kabi has been approved by the FDA.

We were honored to welcome over 100 healthcare professionals from 33 countries to our headquarters for the FRANC2024 Oncology – the Fresenius Kabi Advanced Nutrition Conference.

Learn more about chronic kidney disease and how health care professionals play a crucial role in early detection and patient education.

Fresenius Kabi’s ustekinumab biosimilar Otulfi® (ustekinumab-aauz), developed by Formycon AG, is now available in the United States and European Union.

FY/24: Upgraded outlook achieved, consistent financial performance with profitable growth.

With this mentoring program, Fresenius Kabi supports early-career clinicians and researchers through education, networking, and funding opportunities.

To further advance research and medical education in the field of intensive care medicine, Fresenius Kabi continues its collaboration with ESICM in 2025.

Fresenius, via its operating company Fresenius Kabi, announced today that the U.S. FDA has granted 510(k) clearance to its Adaptive Nomogram.

Fresenius Kabi is a Top Employer in 2025, with twelve countries receiving certification from the Top Employers Institute.

Fresenius, through its operating company Fresenius Kabi, is broadening its growing biopharma portfolio through a new licensing agreement with South Korea’s SamChunDang Pharm (SCD).

Fresenius, through its operating company Fresenius Kabi, announced today that Epinephrine Injection, USP, is now available in the United States.

New collaboration showcases successful integration of Ori's IRO Platform with Cue and Lovo processing systems to enhance efficiency in CGT manufacturing

By increasing awareness of responsible antibiotic use, Fresenius Kabi is helping to improve patient outcomes and reduce the risk of antimicrobial resistance.

Michael Sen, CEO of Fresenius: "Team Fresenius delivered an excellent third quarter in 2024 – all financial metrics improved versus the prior year."

Discover how Tanya and Bela lead the Women’s VOICE EIG in the U.S., empowering women and raising awareness about breast cancer through advocacy and support.

Fresenius Kabi wins prestigious sustainability award at Berlin’s Sustainability Kongress 2024 for innovative CO₂ reduction project at Friedberg manufacturing plant.

Development agreement signed to leverage expertise and support cell therapy developers in the large-scale production of their therapies.

The winner of the Fresenius Kabi Clinical Nutrition Award, Dr. Sandra Emily Stoll from Cologne, Germany, has received the €20,000 research grant at ESICM 2024.

Otulfi™ received FDA approval for both subcutaneous and intravenous formulations, to treat the same conditions as Stelara®.

Otulfi® received European Commission (EC) approval for both subcutaneous and intravenous formulations, providing a high-quality treatment option for European patients treated with ustekinumab

Fresenius Kabi showcases commitment to improving patient care through holistic expertise in medical nutrition and its innovative solutions at ESPEN.

Paola Gava, a nursing student from Germany, was honored with the Queen Silvia Nursing Award for her innovative dementia care online platform, MED-DEM.

Innovative digital technology like data matrix barcodes or RFID labels is streamlining inventory processes in hospitals, ultimately contributing to patient safety

Fresenius Kabi is a sponsor of the Athlon Institute in São José dos Campos, Brazil, which is sending 20 athletes to the 2024 Paralympics.

This award recognizes a Premier Inc. national contracted supplier that uses or deploys innovative and scalable methods and technology to accelerate clinical evidence into real-world practice.

Major progress on deleveraging on the back of strong cash flow: entering target ratio corridor; outlook confirmed and optimistic about second half.

Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommends approval of FYB202 for the treatment of severe inflammatory diseases.

European Medicines Agency has accepted for review the Marketing Authorization Applications for the biosimilar candidates of Prolia® (denosumab) and Xgeva® (denosumab)

The Championship Day is a competition for our employees to drive positive change. Many ideas that are improving our environmental performance are implemented.

The subcutaneous formulation of the tocilizumab biosimilar provides increased access and an affordable treatment option for U.S. patients.

Celebrate World Blood Donor Day with Fresenius Kabi. Discover our global impact on blood donation and how we’re saving lives, one drop at a time.

Read our new whitepaper on Infusion Systems and Interoperability in Healthcare Systems – A perspective in use cases and an analysis of applicable standards

U.S. Food and Drug Administration has accepted for Review of Biologics License Application for our Denosumab Biosimilar Candidate

Group outlook raised for FY/24 due to the excellent first quarter and a better than originally expected operating performance for the remainder of the financial year 2024.

Join our clinical nutrition program for research, mentorship, and a chance to win a €250,000 grant.

Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®*, its Third Approved Biosimilar in the U.S.

Fresenius Kabi has launched the JUMPstart Renal Nutrition Therapy Research Program to facilitate more studies in nutritional interventions for CKD.

Fresenius Kabi and Formycon have reached a settlement agreement with Johnson & Johnson for FYB202, a proposed ustekinumab biosimilar to Stelara in Europe and Canada.

Tyenne® becomes Fresenius Kabi's first tocilizumab biosimilar with both IV and subcutaneous formulations approved by the FDA.

Fresenius Kabi and Prange Group have completed the transfer of ownership of the former Fresenius Kabi plant in Halden, Norway, to HP Halden Pharma AS.

To further foster research and medical training in intensive care, we continue our collaboration with the European Society for Intensive Care Medicine.

Fresenius achieves its raised FY/23 outlook with a strong final quarter. Read more about Fresenius' fourth quarter performance and strategic priorities in 2024.

Experience the continued growth and collaboration within the JUMPstart alumni community. Discover the past activities and find out what awaits you in 2024.

Fresenius Kabi is a Top Employer in 2024, with nine countries receiving certification from the Top Employers Institute.

Fresenius Kabi and Mayo Clinic have signed a multiyear contract for the Ivenix Infusion System. Learn how this collaboration impacts the healthcare sector.

Announcement of Fresenius Kabi and its license partner Formycon: FDA has accepted Ustekinumab biosimilar candidate for review.

Fresenius Kabi, one of the leading manufacturers of intravenously administered generic antibiotics, takes active measures to fight antimicrobial resistance.

Fresenius delivers strong third quarter performance and improves operating earnings outlook

Tyenne® becomes the first tocilizumab biosimilar available in Europe for the treatment of several inflammatory and immune diseases.

Demands for plant-based alternatives: Fresubin® Plant-Based supports individuals with or at risk of malnutrition, while respecting dietary preferences.

Fresenius Kabi is excited to announce that Prof. Arthur van Zanten, MD Ph.D., is the recipient of the € 20,000 grant at the ESICM Clinical Nutrition Award

Fresenius Kabi and its license partner Formycon AG announce that the European Medicines Agency has accepted the Marketing Authorization Application for FYB202.

Fresenius Kabi announced that the European Commission (EC) granted marketing authorization for its tocilizumab biosimilar Tyenne®.

Fresenius Kabi is a Top Employer, with six countries receiving certification from the Top Employers Instititute.

Fresenius Kabi has signed an agreement with Virginia Oncology Associates to purchase the Ivenix Infusion System to deliver medications for its patients.

Fresenius Kabi’s JUMPstart Clinical Nutrition Award winner is announced at ESPEN congress: Lee Zheng Yii receives 250,000 Euro research grant for his fish oil nutrition study.

Fresenius Kabi and Lupagen Inc. have entered into an agreement for technologies designed to bring the delivery of cell and gene therapies closer to the patient.

Recently launched blood bag system not made with DEHP addresses market needs and is subject of an award-winning clinical study.

Fresenius Kabi and Formycon AG entered into a settlement agreement with Johnson & Johnson concerning FYB202, a proposed ustekinumab biosimilar in the U.S.

Explore the incredible impact of blood donation. Watch what our heroes think about during blood or plasma donation and read about our blood donation events.

Operating Companies Showing Consistent Performance; Group Simplification Delivered

Fresenius Kabi’s tocilizumab biosimilar candidate MSB11456 receives positive CHMP opinion.

Fresenius Kabi’ denosumab biosimilar candidate FKS518 shows positive clinical trial results.

Fresenius Kabi announced today the launch of its citrate-free biosimilar Idacio (adalimumab-aacf).

Today is World Blood Donor Day - find out more about the constant need for blood and plasma donations and watch the interview with Pierre Vidal.

Fresenius SE hosts Kabi Capital Markets Day Event, presenting the future path towards a sustainable value creation and strategies for #FutureFresenius.

Fresenius Kabi secures Premier's Technology Breakthrough agreement, reinforcing their unwavering dedication to innovation and excellence in healthcare.

Fresenius Kabi will be present at the Euroanaesthesia 2023 with a booth and symposium about best practice for ICU sedation and sustainable anesthesia.

Fresenius Kabi fuels nutritional research with a $100,000 grant, driving innovation in the field. Explore the steadfast commitment to advancement now.

Strong Performance Of Operating Companies in Q1/23 and Structural Simplification on Track

Watch a video about Fresenius Kabi's humanitarian efforts in ongoing earthquake relief initiatives through the donation of essential medical supplies.

Fresenius Kabi introduces a single-needle venous access option for the Amicus® Extracorporeal Photopheresis System, enhancing healthcare possibilities.

Vizient Innovative Technology contract awarded to Fresenius Kabi for the Ivenix infusion system. The contract sets terms for hospitals to buy the system.

Fresenius Kabi's compassionate humanitarian aid for Ukraine, showcasing their unwavering commitment to assisting those in need during challenging times.

Fresenius strengthens its management board team with new appointments at Fresenius Kabi and an expansion of the Human Resources and Legal department.

Fresenius sets a new direction for the future with new strategies and a new, rigorous financial framework in its press report for the fiscal year 2022.

Fresenius Kabi announces the launch of pegfilgrastim biosimilar Stimufend® in the U.S., expanding access to quality healthcare solutions against cancer.

Get inspired by Lizl Veldsman, JUMPstart winner 2019 with her research project on clinical nutrition and read her advices for future female researchers.

The Fresenius Group sends its deepest symphaties and condolences to people affected by the earthquake in Türkiye and Syria and donates lifesaving products.

Ivenix Infusion System is the subject of a recent KLAS report, showing that U.S. customers are highly satisfied with the technologically advanced system.

Fresenius Kabi and Formycon partner globally to commercialize Ustekinumab biosimilar, expanding access to affordable healthcare solutions worldwide.

Sonja Meyers idea "getAgo" a waterproof zip toiletry bag wins the queen silvia nursing award in spring 2023. Read more about the award and her idea here.

To remain a responsible and successful company, Fresenius Kabi's Vision 2026 is the foundation for a sustainable growth strategy for the next decade.

Fresenius Kabi gets U.S. FDA approval for their biosimilar Idacio®, a citrate-free formulation of adalimumab which use is for chronic autoimmune diseases.

Read more about the upcoming third wave of Fresenius Kabi's research grant in clinical nutrition, starting december 2022 and what a JUMPstart is in general.

Fresenius Kabi achieves new important milestone with the extension of the 4th MedTech manufacturing facility at PIISA in Haina in the Dominican Republic.

Weak third quarter for Fresenius Kabi due to ongoing challenging macroeconomic enviroment. Fresensius responds with realignment of business activities.

Fresenius Kabi employees in the US, Italy, France, Haina, Brasil and more have shown their commitment for Breast Cancer Awareness Month in different ways.

Explore how Fresenius Kabi supports young patients and their families with creative learning experiences about nutritions at Children's Hospital in Cairo.

Fresenius Kabi announces that the FDA has approved its pegfilgrastim biosimilar, Stimufend® which is a high-quality treatment option for cancer patients.

Fresenius appoints Michael Sen as the successor of the former CEO Stephan Sturm. He will take up his new position at the beginning of October 2022.

Fresenius Kabi announces EMA acceptance for biosimilar MSB11456, which is a new addition to a compelling biosimilar portfolio against autoimmune diseases.

Fresenius Kabi announces a partnership with Fiocruz/Bio-Manguinhos for the production of adalimumab biosimilar, IDACIO in Brazil for autoimmune diseases.

Preliminary and financial results for the second quarter and first half of 2022 and more on how Fresenius Kabi is meeting the overall economic challenges.

The FDA has accepted for review Fresenius Kabi’s Biologics License Application for the company’s biosimilar candidate of tocilizumab.

Fresenius Kabi's successful majority stake acquisition of mAbxience marks a significant step in their commitment to healthcare innovation and excellence.

Fresenius Kabi revises outlook for group guidance 2022 due to increased wage inflation, labor shortage and overall worsened macrooeconomic enviroment.

Explore, what the Austrian broadcasting cooperation's video shoot for its series "The future makers" was like and get an insight into the Styrian industry.

For ten years Fresenius Kabi China organises nationwide blood donation activities with an increasing number. Our promise Committed to Life at its best.

Fresenius Kabi continues its efforts to provide humanitarian aid to Ukraine and recently donated about 70 pallets of urgently needed lifesaving medicines.

New data from the EuroPN study shows that early medical nutrition therapy with moderate daily calorie and protein intakes improves clinical outcomes.

Successful start for Fresenius Kabi in 2022, despite macrooeconomic challenges – Read all information about financial growth and market developements.

Fresenius Kabi completes the acquisition of Ivenix which provides state-of-the-art and industry leading offerings in infusion therapy for the U.S market.

Fresenius Kabi and the U.S. company Cerus Corporation signed a new agreement for the production of systems for pathogen inactivation in blood components.

Fresenius Kabi buys a majority stake in mAbxience and acquires Ivenix which significantly enhances their presence in high-growth biopharmaceuticals market.

Fresenius Kabi announces that the European Commission granted marketing authorization for Stimufend® which offers a high-quality option for cancer patients.

Read about the current status of humanitarian aid for Ukraine and Fresenius Kabi's contribution to the emergency treatment and care of patients on site.

Successful annual financial statements and positive outlook for fiscal year 2022 for Fresenius Kabi – Strategic evaluation shows path to accelerated growth.